WESTFORD, Mass., July 31,
2024 /PRNewswire/ -- According to SkyQuest, the
global Liquid Biopsy Market was valued at around USD 9.28 billion in 2022 and is expected to rise
from USD 10.32 billion in 2023 to
reach a value of USD 24.14 billion by
2031, at a CAGR of 11.21% during the forecast period
(2024–2031).
The liquid biopsy market has gained tremendous traction, due to
the increasing incidence of cancer worldwide and demand for faster,
less invasive diagnostic methods. In the US. the burden of
non-small cell lung cancer has recently emerged as the highest
burden of lung cancer subtype in the country statistics show that
12.8 million new cases of non-small cell lung cancer were diagnosed
in the United States.
Furthermore, the increasing adoption of liquid biopsy signals an
expansion in generalized medicine and cancer precision. These new
diagnostic methods offer advantages over traditional biopsies
analyzes body by real-time monitoring of disease progression and
treatment response, providing timely intervention strategies such
as early detection and prioritization. The liquid biopsy market is
poised for further growth with advances in technology, expanded
research efforts, driven by increased awareness of healthcare
providers and patients.
Download a detailed overview:
https://www.skyquestt.com/sample-request/liquid-biopsy-market
Liquid Biopsy Market Overview:
Report
Coverage
|
Details
|
Market Revenue in
2023
|
USD 10.32
Billion
|
Estimated Value by
2031
|
USD 24.14
Billion
|
Growth Rate
|
Poised to grow at a
CAGR of 11.21%
|
Forecast
Period
|
2024–2031
|
Forecast
Units
|
Value (USD
Billion)
|
Report
Coverage
|
Revenue Forecast,
Competitive Landscape, Growth Factors, and Trends
|
Segments
Covered
|
Product &
Services, Circulating Biomarker, Clinical Application, Technology,
Application, Sample Type, End User and Region
|
Geographies
Covered
|
North America, Europe,
Asia Pacific, Latin America, and Middle East and Africa.
|
Report
Highlights
|
Updated financial
information / product portfolio of players
|
Key Market
Opportunities
|
Increasing Adoption of
Next-generation Sequencing (NGS) Technology
|
Key Market
Drivers
|
Increasing Prevalence
of Chronic Diseases
|
Segments covered in Liquid Biopsy Market are as
follows:
- Product & Services
-
- Assay Kits, Instruments, and services
- Circulating Biomarker
-
- Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA,
Extracellular Vesicles, and Others
- Clinical Application
-
- Early Cancer Screening, Therapy Selection, Treatment
Monitoring, and Recurrence Monitoring
- Technology
-
- Multi-Gene Parallel Analysis using NGS, and Single-Gene
Analysis using PCR
- Application
-
- Cancer Application (Lung Cancer, Breast Cancer, Colorectal
Cancer, Prostate Cancer, Melanoma, and Others), Non-Cancer
Application (Non-Invasive Prenatal Testing, Organ Transplantation,
and Infectious Disease Testing)
- Sample Type
-
- Blood Samples, Urine Sample, Saliva Sample, and Others
- End User
-
- Hospitals & Clinics, Diagnostic Centers, Reference
Laboratories, Academic & Research Centers, and Others
Request Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/liquid-biopsy-market
Hospitals and Clinics: Revolutionizing Patient Care with
Non-Invasive Diagnostics
The key segment in the liquid biopsy market is the hospitals and
clinics segment, which is expected to account for the largest
market share owing to increasing adoption of liquid biopsy tests
for cancer diagnosis and medical diagnosis. Widespread growth and
the need for developed treatment options for everyone are some of
the major reasons for the demand for urine biopsies in hospitals
and clinics.
Within the liquid biopsy market, the diagnostic center segment
is expected to grow at the highest rate. These centers provide
patients with advanced specialized diagnostic services and other
urine biopsies. These diagnostic centers have the advantage of
offering shorter wait times, turnaround times, specialist
knowledge, and state-of-the-art equipment, solutions that encourage
more people to turn to this center for diagnosis is accurate and
timely. These diagnostic centers are expected to develop and grow
rapidly in the coming years, re-establishing themselves as key
players in the aquatic biopsy market landscape.
View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/liquid-biopsy-market
Assay Kits: Empowering Precision Medicine with Cutting-Edge
Tools
The dominant segment in the liquid biopsy market is the assay
kits segment, which is expected to hold the largest market share
owing to the high demand for liquid biopsy tests, especially for
non-sensitive cancer detection, versatility, cost-effectiveness,
continuous. Factors such while technological advancement leads to
greater market share for research products Increasing prevalence of
cancer worldwide and need for early diagnosis and personalized
treatment options are some of the major factors driving the demand
for artificial fluids inspection and reagents.
The fastest growing segment in the liquid biopsy market is the
instruments segment. This is due to the increasing demand for
practical and high-throughput liquid physiology systems that can
process large numbers of samples in a short period of time as well
as, technological advances, such as next generation delivery use
sequencing (NGS) and digital PCR (dPCR), which are highly
efficient.
Liquid Biopsy Market: Pioneering a New Era in Precision
Medicine
The liquid biopsy market is changing the way cancer is diagnosed
and treated. The technology's ability to detect genetic mutations,
monitoring treatment response and detecting minimal residual
disease ensures interventions for patients that are personalized
and timely as research and technology continues to advance. The
liquid biopsy market is poised for growth and promises a future
where cancer services are more accurate, more dynamic and more
accessible to patients.
Related Report:
Breast Biopsy Market
Cancer Diagnostics Market
Digital Pathology Market
Bioanalytical Testing Services Market
Cancer Immunotherapy Market
About Us:
SkyQuest is an IP focused Research and Investment Bank and
Accelerator of Technology and assets. We provide access to
technologies, markets and finance across sectors viz. Life
Sciences, CleanTech, AgriTech, NanoTech and Information &
Communication Technology.
We work closely with innovators, inventors, innovation seekers,
entrepreneurs, companies and investors alike in leveraging external
sources of R&D. Moreover, we help them in optimizing the
economic potential of their intellectual assets. Our experiences
with innovation management and commercialization has expanded our
reach across North America,
Europe, ASEAN and Asia Pacific.
Contact:
Mr. Jagraj Singh
SkyQuest Technology
1 Apache Way,
Westford,
Massachusetts 01886
USA (+1) 351-333-4748
Email: sales@skyquestt.com
Visit Our Website: https://www.skyquestt.com/
Logo :
https://mma.prnewswire.com/media/2446095/SkyQuest_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/liquid-biopsy-market-rising-adoption-to-propel-11-21-cagr-by-2031--skyquest-technology-302210935.html
SOURCE SkyQuest Technology